Fig. 3.

Proposed new follow-up schedules. (A) Patients with stage I seminoma on active surveillance or after adjuvant carboplatin. (B) Patients with low- or high-risk stage I nonseminoma on active surveillance. (C) Patients with stage I nonseminoma after adjuvant chemotherapy and patients with metastatic seminoma/nonseminoma with good prognosis (International Germ Cell Cancer Collaborative Group classification) after treatment completion. Late toxicity checks include weight, blood pressure, kidney function, testosterone levels, lipid profile, and assessment for secondary malignancies. CT = computed tomography; MRI = magnetic resonance imaging. ^a Only in year 5 (60 mo). ^b Only in cases with high-risk disease/lymphovascular invasion. ^c Chest CT instead of X-ray in cases with lung metastases at diagnosis.